# Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

> **NCT02396108** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 55 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel + Carboplatin + ASLAN001

## Key facts

- **NCT ID:** NCT02396108
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2018-03
- **Final completion:** 2019-03
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2017-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396108, "Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02396108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*